Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 1403 Nifty 500 stocks· EOD 2026-06-19

Bal Pharma Limited

BALPHARMA · NSE · Healthcare

₹86.83
-0.96 (-1.09%)
Buy zoneSell
The bottom line

StocksWizard rates Bal Pharma Limited a Sell, scoring 40/100 on our blended model. At ₹86.83 it trades below our blended DCF and relative-multiples fair value of ₹173.66, implying roughly 100% upside to that estimate — we read the stock as undervalued by 100%. Financial health scores 10/100 (grade F), with a Piotroski F-score of 3/9. It clears 4 of 12 investability checks, with durability 17, valuation 86 and momentum 88 on our 0–100 scales.

These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Our verdictSolvency risk
Sell40/100
Quality17
Valuation93
Momentum88
Financial trend13
Intrinsic value
Our fair value
₹173.66
Undervalued by 100%
Price ₹86.83Range ₹43.42₹187.55

With a 20% margin of safety, our buy-below price is ₹138.93. Low-confidence estimate — limited data.

F
Financial health 10/100
From leverage, liquidity & coverage ratios

Piotroski F-score 3/9 — quality of earnings & balance sheet.

Investability checklist

Passed 4 of 12 checks33/100
  • ROE above 15%7.9%
  • Low debt (D/E < 0.5)2.01x
  • Positive free cash flow
  • Revenue growth > 10%3%
  • Earnings growing-34%
  • Net margin ≥ 10%2.0%
  • Current ratio > 1.51.05
  • Below our fair value
  • Margin of safety ≥ 20%
  • Above 200-day average
  • Above 50-day average
  • Positive 1-year return
  • Altman Z in safe zone
  • Piotroski ≥ 73/9

1-year price

EOD · 2026-06-19
1W
+0.7%
1M
+2.0%
3M
+30.9%
6M
+18.1%
1Y

Our scores

Durability17
Valuation86
Momentum88

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Shareholding

Promoter65.5%
Institutions0.0%
Public & other34.5%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹138 Cr
P/E ratio
22.0
P/B ratio
1.68
EPS (TTM)
₹3.95
ROE
7.9%
Debt / Equity
2.01x
Profit margin
2.0%
Free cash flow
₹-12 Cr
52-week high
₹102.2
-15.04% from high
52-week low
₹60.42
Dividend yield
1.4%
Beta
0.49

SWOT snapshot

Weaknesses

  • Low return on equity (7.9%).
  • High debt relative to equity.
  • Weak Piotroski score (3/9).

Opportunities

  • Trading in our value buy zone versus sector peers.
  • Trades ~100% below our estimated fair value.

Threats

  • Earnings contracting year on year.

About Bal Pharma Limited

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care pro

More in Healthcare

All stocks

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.